{
    "clinical_study": {
        "@rank": "62096", 
        "arm_group": [
            {
                "arm_group_label": "Obex, a nutritional supplement", 
                "arm_group_type": "Experimental", 
                "description": "Obex will be administered two sachets daily dissolved in a glass of water, 30 minutes before lunch and dinner during two months. Patients will be recommended to comply with a healthy lifestyle through diet and exercise."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo will be administered two sachets daily dissolved in a glass of water, 30 minutes before lunch and dinner during two months. Patients will be recommended to comply with a healthy lifestyle through diet and exercise."
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of the study is to evaluate the effects of a dietary supplement (Obex\u00ae) on\n      anthropometric and physiological variables in Spanish women between 35 and 60 years who are\n      overweight or obese."
        }, 
        "brief_title": "Obex, a Nutritional Supplement, in Overweight and Obese Spanish Women", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "condition": [
            "Obesity", 
            "Overweight"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Obesity", 
                "Overweight"
            ]
        }, 
        "detailed_description": {
            "textblock": "The nutritional supplement consists of natural plant extracts such as Caralluma fimbriata,\n      Phaseolus vulgaris, Acai Berry and other antiobesity agents: ornithine, carnitine fumarate,\n      essential fatty acids and certain amino acids, vitamins and minerals."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Women aged between 35 and 60 years.\n\n          -  Body Mass Index (BMI) greater than 27 kg/m\u00b2 and lower than 35 kg/m\u00b2\n\n          -  Ability to provide informed consent\n\n        Exclusion Criteria:\n\n          -  Presence of any endocrine, hepatic, renal or cardiovascular disease.\n\n          -  History of bariatric surgery\n\n          -  Pregnancy or lactation\n\n          -  Concomitant disease with reduced life expectancy\n\n          -  Severe psychiatric conditions\n\n          -  Drug dependence"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "35 Years"
        }, 
        "enrollment": {
            "#text": "92", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01934036", 
            "org_study_id": "HOPE_TRIAL1"
        }, 
        "intervention": [
            {
                "arm_group_label": "Obex, a nutritional supplement", 
                "description": "After concluded the two months of treatment, patients will be follow-up during three months without consumption of Obex.", 
                "intervention_name": "Obex", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "After concluded the two months of treatment, patients will be follow-up during three months without consumption of the placebo.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Weight loss", 
            "Nutritional supplement", 
            "Waist", 
            "Body composition", 
            "Skinfolds"
        ], 
        "lastchanged_date": "February 24, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Ciudad Universitaria de Cantoblanco", 
                    "country": "Spain", 
                    "state": "Madrid", 
                    "zip": "28049"
                }, 
                "name": "Universidad Aut\u00f3noma de Madrid"
            }
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "2", 
        "official_title": "Efficacy and Safety of Obex\u00ae, a Nutritional Supplement, in Overweight or Obese Women", 
        "overall_official": {
            "affiliation": "Universidad Auton\u00f3noma de Madrid", 
            "last_name": "Consuelo Prado, Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Spain: Agencia Espa\u00f1ola de Seguridad Alimentaria y Nutrici\u00f3n", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The primary outcome is to evaluate the effect of the treatment with OBEX on skinfold thickness of the biceps, triceps, subscapular and suprailiac as compared to placebo group at 2 months of treatment.", 
            "measure": "To evaluate the effect of OBEX on skinfolds", 
            "safety_issue": "No", 
            "time_frame": "Two months of treatment and three months after concluded the treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01934036"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Waist and Hip circumferences will be measured at baseline and at the end of treatment.", 
                "measure": "To evaluate the effect of OBEX on the waist and hip circumferences", 
                "safety_issue": "No", 
                "time_frame": "Two months of treatment and three months after concluded the treatment"
            }, 
            {
                "description": "The arm circumference will be measured at baseline and at the end of treatment.", 
                "measure": "To evaluate the effect of Obex on the arm circumference.", 
                "safety_issue": "No", 
                "time_frame": "Two months of treatment and three months after concluded the treatment"
            }, 
            {
                "description": "Body fat (%) will  be assessed at baseline and the end of treatment", 
                "measure": "To evaluate the effect of Obex on the percentage of body fat", 
                "safety_issue": "No", 
                "time_frame": "Two months of treatment and three months after concluded the treatment"
            }, 
            {
                "description": "The muscular mass will be measured at baseline and at the end of treatment.", 
                "measure": "To evaluate the effect of Obex on the muscular mass", 
                "safety_issue": "No", 
                "time_frame": "Two months of treatments and three months after concluded the treatment"
            }, 
            {
                "description": "The arterial BP will be evaluated at baseline and at the end of treatment.", 
                "measure": "To evaluate the effect of Obex on arterial blood pressures.", 
                "safety_issue": "No", 
                "time_frame": "Two months of treatment and three months after concluded the treatment"
            }, 
            {
                "description": "The fasting glucose and cholesterol levels will be evaluated at baseline and at the end of treatment.", 
                "measure": "To evaluate the effect of Obex on fasting glucose and cholesterol levels", 
                "safety_issue": "No", 
                "time_frame": "Two months of treatment and three months after concluded the treatment"
            }
        ], 
        "source": "Catalysis SL", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Catalysis SL", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}